Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJulie R. Brahmer, John A. Thompson, Christina Lacchetti et al.|Journal of Clinical Oncology|2018Cited by 3.7k
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trialsTimothy A. Yap, Marina Konopleva, Zhenlin Ju et al.|Nature Medicine|2023Cited by 372
FGFR a promising druggable target in cancer: Molecular biology and new drugsRut Porta, Christian Rolfo, Roberto Borea et al.|Critical Reviews in Oncology/Hematology|2017Cited by 203
Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancerChristian Rolfo, Aung Naing, Elisa Giovannetti et al.|npj Precision Oncology|2023Cited by 146
Phase 2 study of pembrolizumab in patients with advanced rare cancersAung Naing, Mouhammed Amir Habra, Funda Meric‐Bernstam et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 130